Investor Relations

Investor Presentation

Platform

At the core of Medicenna’s therapies are interleukins (IL-2, IL-4 and IL-13), which are engineered to be highly specific and fused with other molecules to enhance their function. In doing so, they become powerful and proprietary tools called Superkines that can modulate, fine-tune and empower the immune system to fight cancer, autoimmune and neuroinflammatory diseases.

Data Provided by Refinitiv. Minimum 15 minutes delayed.